
Solid Tumor Program
Our Pediatric Solid Tumor Program provides specialized evaluation, diagnosis and care for children, teens and young adults with solid tumors, including neuroblastoma, hepatoblastoma, bone and soft tissue sarcomas, Wilms' tumors and other cancers. We also care for patients whose cancers have relapsed. Our team is known globally for taking on rare and challenging cases.
At UCSF, we believe cancer therapy works best when it is tailored to each patient's disease. Every one of our patients is unique, and our program offers high-quality, targeted care that is precise, effective and compassionate. We evaluate patients using the most advanced diagnostic tools, including genetic tests developed here at UCSF and not offered at other hospitals. Our patients also have access to new treatments that aren't widely available or that are still being evaluated in clinical trials. We're the only hospital in Northern California that's a member of the Oncology Group Phase 1/Pilot Consortium, a small group of leading institutions tasked by the National Cancer Institute with developing new therapies for pediatric cancers.
Our team understands that cancer treatment is an intensely personal experience for each child and family. That's why we draw on the expertise of nurse practitioners, psychologists, social workers and child life specialists to ensure that you and your child receive the support you need. It's also why we strive to make as much of your child's care as possible happen close to home – through telehealth and collaboration with health care providers in your community.
Our locations (1)
Our team
-
Robert E. Goldsby
MD
Pediatric hematologist-oncologist -
Katherine K. Matthay
MD
Pediatric hematologist-oncologist -
Arun Rangaswami
MD
Pediatric hematologist-oncologist -
Amit J. Sabnis
MD, MS
Pediatric hematologist-oncologist -
Alejandro Sweet-Cordero
MD
Pediatric hematologist-oncologist -
Kieuhoa T. Vo
MD
Pediatric hematologist-oncologist -
Cynthia Burke
NP
Pediatric nurse practitioner -
Fabienne Hollinger
NP
Family nurse practitioner
Awards & recognition
-
Best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
-
patients treated with MIBG therapy, a leading-edge neuroblastoma treatment
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Related clinics (7)

Precision Cancer Medicine Program

Hematology Clinic

Orthopedic Surgical Oncology Clinic

Blood & Marrow Transplant (BMT) Clinic
Support services
Clinical trials
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and D...
The number of patients experiencing a cycle 1 dose limiting toxicity at least possibly attributable to tegavivint by study part and dose level.
Recruiting
More about this studyCBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymp...
Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CBL0137 in children with relapsed or refractory solid tumors including CNS tumors and lymphoma.
Recruiting
More about this studyA Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine f...
Frequency percent (%) of patients with acute myeloid leukemia (AML) in second or greater relapse or refractory to relapse therapy who experience a cycle 1 dose limiting toxicity to imetelstat administered in combination with fluda...
Recruiting
More about this studyTiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Def...
Frequency (%) of pediatric patients (<18 years) with cycle 1 dose limiting toxicities attributable to tiragolumab as monotherapy in the safety cohort (Part A).
Recruiting
More about this studyVincristine Pharmacokinetics in Infants
Estimate (95% CI) of the mean area under the concentration time curve for the elimination phase assessed at 0, 2, 6-8, and 18-24 hours after vinCRISTine dose by age group.
Recruiting
More about this studyFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurren...
To establish the recommended Phase II dose of a flavored preparation of orally administered irinotecan VAL-413 (Orotecan®) when given in combination with temozolomide for 5 consecutive days
Recruiting
More about this studyMobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
The knowledge of the participant will be measured using a 12-item questionnaire that assesses the awareness of their treatment and health issues in four categories: (1) diagnosis, (2) treatment, (3) risks, and (4) recommended foll...
Recruiting
More about this studyBiomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglion...
Life tables, Kaplan-Meier survival curves, log-rank tests, and Cox regression will be used to explore the relationship of laboratory variables to outcome.
Recruiting
More about this studyLong-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
More about this studyOur research initiatives
Saving future lives
500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.
